Rapamycin-loaded poly(ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone) nanoparticles: Preparation, characterization and potential application in corneal transplantation

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 4, 2014, Pages 557-563

  Zhang, Zhaoliang ^a   Xu, Lu ^a   Chen, Hao ^a   Li, Xingyi ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

corneal transplantation; nanoparticles; polymer; rapamycin

Indexed keywords

CORNEAL TRANSPLANTATION; NANOPARTICLES; POLYMER; RAPAMYCIN;

ANIMALS; CELL LINE; CHEMISTRY, PHARMACEUTICAL; CORNEAL TRANSPLANTATION; DRUG DELIVERY SYSTEMS; GRAFT REJECTION; HUMANS; NANOPARTICLES; POLYESTERS; POLYETHYLENE GLYCOLS; SIROLIMUS;

EID: 84899070791     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12089     Document Type: Article

References (26)

1. Guba M, etal. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135.
2. Luderer F, etal. Biodegradable sirolimus-loaded poly (lactide) nanoparticles as drug delivery system for the prevention of in-stent restenosis in coronary stent application. J Biomater Appl 2013; 25: 851-875.
3. Raval A, etal. Preparation and optimization of media using Pluronic micelles for solubilization of sirolimus and release from the drug eluting stents. Colloids Surf B 2012; 93: 180-187.
4. Cerovac V, etal. The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res 2010; 70: 666-674.
5. Kahan B,. Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment. Expert Opin Drug Saf 2011; 10: 727-749.
6. Pang X, etal. Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res 2010; 70: 1951-1959.
7. Cloughesy TF, etal. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS ONE 2008; 5: e8.
8. Rizzieri DA, etal. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008; 14: 2756-2762.
9. Byrne RA, etal. Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. Heart 2009; 95: 1489-1494.
10. Steigerwald K, etal. The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts. Biomaterials 2009; 30: 632-637.
11. Phillips BN, Wroblewski KJ,. A retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis. J Ophthalmic Inflamm Infect 2011; 1: 29-34.
12. Zhang Z, etal. Low dose rapamycin exacerbates autoimmune experimental uveitis. PLoS ONE 2012; 7: e36589.
13. Abdur Rouf M, etal. Rapamycin-cyclodextrin complexation: improved solubility and dissolution rate. J Incl Phenom Macro Chem 2011; 70: 167-175.
14. Elsaid N, etal. Positively charged amphiphilic chitosan derivative for the transscleral delivery of rapamycin. Invest Ophthalmol Vis Sci 2012; 53: 8105-8111.
15. Kauffman KJ, etal. Optimization of rapamycin-loaded acetalated dextran microparticles for immunosuppression. Int J Pharm 2012; 422: 356-363.
16. Jia WJ, etal. Preparation of biodegradable polycaprolactone/poly (ethylene glycol)/polycaprolactone (PCEC) nanoparticles. Drug Deliv 2008; 15: 409-416.
17. Rao JP, Geckeler KE,. Polymer nanoparticles: preparation techniques and size-control parameters. Prog Polym Sci 2011; 36: 887-913.
18. Wei X, etal. Self-assembled honokiol-loaded micelles based on poly (ε-caprolactone)-poly (ethylene glycol)-poly (ε-caprolactone) copolymer. Int J Pharm 2009; 369: 170-175.
19. Kehoe S, etal. FDA approved guidance conduits and wraps for peripheral nerve injury: a review of materials and efficacy. Injury 2012; 43: 553-572.
20. Wei X, etal. Biodegradable poly (ε-caprolactone)-Poly (ethylene glycol) copolymers as drug delivery system. Int J Pharm 2009; 381: 1-18.
21. Xu B, etal. Amphiphilic biodegradable poly (ε-caprolactone)-poly (ethylene glycol)-poly (ε-caprolactone) triblock copolymers: synthesis, characterization and their use as drug carriers for folic acid. Polym Bull 2010; 64: 537-551.
22. Gou M, etal. Poly (ε-caprolactone)-poly (ethylene glycol)-poly (ε-caprolactone)(PCL-PEG-PCL) nanoparticles for honokiol delivery in vitro. Int J Pharm 2009; 375: 170-176.
23. Gou M, etal. Poly (ε-caprolactone)/poly (ethylene glycol)/poly (ε-caprolactone) nanoparticles: preparation, characterization, and application in doxorubicin delivery. J Phys Chem B 2009; 113: 12928-12933.
24. Liu CB, etal. Thermoreversible gel-sol behavior of biodegradable PCL-PEG-PCL triblock copolymer in aqueous solutions. J Biomed Mater Res B 2007; 84: 165-175.
25. Huang Y, etal. In vitro and in vivo performance of a dual drug-eluting stent (DDES). Biomaterials 2010; 31: 4382-4391.
26. Gupta H, etal. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine 2010; 6: 324-333.